Relief of Continuous Chronic Pain by Intraspinal Narcotics Infusion Via an Implanted Reservoir

Dennis W. Coombs, Richard L. Saunders, Michael S. Gaylor, Andrew R. Block, Theodore Colton, Robert Harbaugh, Mark G. Pageau, William Mroz

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Ten patients with intractable pain (five cancer and five nonmalignant) were treated with continuous intraspinal morphine delivered by an implanted continuous infusion system. Both patient groups were evaluated and compared using an identical battery of psychometric examinations administered before and 12 weeks after therapy. The cancer-pain group reported significant reduction in pain on serial visual pain analogue scales at 12 weeks compared with no change in the nonmalignant-pain group reports despite a much lower baseline report in the cancer group. Both groups of patients reduced their oral narcotic requirement significantly during continuous intraspinal morphine infusion. While the cancer patients took more oral narcotic at baseline, at 12 weeks no difference existed in oral intake between the two groups. Both groups required significant serial increases in infused morphine, indicating that spinal opiate receptor tolerance occurs. The results of this study confirm the sustained analgesic efficacy reported earlier in cancer-related pain syndromes, thus supporting further cautious expansion of this therapy within the cancer-related pain population. In contrast, a poor response was seen in the nonmalignant-pain group, consistent with the unsatisfactory responses to many potentially analgetic approaches to chronic nonmalignant pain. We are thus discouraged from further use of this therapy in the patient with chronic nonmalignant pain.

Original languageEnglish (US)
Pages (from-to)2336-2339
Number of pages4
JournalJAMA: The Journal of the American Medical Association
Volume250
Issue number17
DOIs
StatePublished - Nov 4 1983

Fingerprint

Narcotics
Chronic Pain
Morphine
Pain
Intractable Pain
Neoplasms
Opioid Receptors
Pain Measurement
Psychometrics
Analgesics
Therapeutics
Population
Cancer Pain

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Coombs, Dennis W. ; Saunders, Richard L. ; Gaylor, Michael S. ; Block, Andrew R. ; Colton, Theodore ; Harbaugh, Robert ; Pageau, Mark G. ; Mroz, William. / Relief of Continuous Chronic Pain by Intraspinal Narcotics Infusion Via an Implanted Reservoir. In: JAMA: The Journal of the American Medical Association. 1983 ; Vol. 250, No. 17. pp. 2336-2339.
@article{d9d8b03a51824fdd81eaddf2d4b5a5a2,
title = "Relief of Continuous Chronic Pain by Intraspinal Narcotics Infusion Via an Implanted Reservoir",
abstract = "Ten patients with intractable pain (five cancer and five nonmalignant) were treated with continuous intraspinal morphine delivered by an implanted continuous infusion system. Both patient groups were evaluated and compared using an identical battery of psychometric examinations administered before and 12 weeks after therapy. The cancer-pain group reported significant reduction in pain on serial visual pain analogue scales at 12 weeks compared with no change in the nonmalignant-pain group reports despite a much lower baseline report in the cancer group. Both groups of patients reduced their oral narcotic requirement significantly during continuous intraspinal morphine infusion. While the cancer patients took more oral narcotic at baseline, at 12 weeks no difference existed in oral intake between the two groups. Both groups required significant serial increases in infused morphine, indicating that spinal opiate receptor tolerance occurs. The results of this study confirm the sustained analgesic efficacy reported earlier in cancer-related pain syndromes, thus supporting further cautious expansion of this therapy within the cancer-related pain population. In contrast, a poor response was seen in the nonmalignant-pain group, consistent with the unsatisfactory responses to many potentially analgetic approaches to chronic nonmalignant pain. We are thus discouraged from further use of this therapy in the patient with chronic nonmalignant pain.",
author = "Coombs, {Dennis W.} and Saunders, {Richard L.} and Gaylor, {Michael S.} and Block, {Andrew R.} and Theodore Colton and Robert Harbaugh and Pageau, {Mark G.} and William Mroz",
year = "1983",
month = "11",
day = "4",
doi = "10.1001/jama.1983.03340170062030",
language = "English (US)",
volume = "250",
pages = "2336--2339",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "17",

}

Relief of Continuous Chronic Pain by Intraspinal Narcotics Infusion Via an Implanted Reservoir. / Coombs, Dennis W.; Saunders, Richard L.; Gaylor, Michael S.; Block, Andrew R.; Colton, Theodore; Harbaugh, Robert; Pageau, Mark G.; Mroz, William.

In: JAMA: The Journal of the American Medical Association, Vol. 250, No. 17, 04.11.1983, p. 2336-2339.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Relief of Continuous Chronic Pain by Intraspinal Narcotics Infusion Via an Implanted Reservoir

AU - Coombs, Dennis W.

AU - Saunders, Richard L.

AU - Gaylor, Michael S.

AU - Block, Andrew R.

AU - Colton, Theodore

AU - Harbaugh, Robert

AU - Pageau, Mark G.

AU - Mroz, William

PY - 1983/11/4

Y1 - 1983/11/4

N2 - Ten patients with intractable pain (five cancer and five nonmalignant) were treated with continuous intraspinal morphine delivered by an implanted continuous infusion system. Both patient groups were evaluated and compared using an identical battery of psychometric examinations administered before and 12 weeks after therapy. The cancer-pain group reported significant reduction in pain on serial visual pain analogue scales at 12 weeks compared with no change in the nonmalignant-pain group reports despite a much lower baseline report in the cancer group. Both groups of patients reduced their oral narcotic requirement significantly during continuous intraspinal morphine infusion. While the cancer patients took more oral narcotic at baseline, at 12 weeks no difference existed in oral intake between the two groups. Both groups required significant serial increases in infused morphine, indicating that spinal opiate receptor tolerance occurs. The results of this study confirm the sustained analgesic efficacy reported earlier in cancer-related pain syndromes, thus supporting further cautious expansion of this therapy within the cancer-related pain population. In contrast, a poor response was seen in the nonmalignant-pain group, consistent with the unsatisfactory responses to many potentially analgetic approaches to chronic nonmalignant pain. We are thus discouraged from further use of this therapy in the patient with chronic nonmalignant pain.

AB - Ten patients with intractable pain (five cancer and five nonmalignant) were treated with continuous intraspinal morphine delivered by an implanted continuous infusion system. Both patient groups were evaluated and compared using an identical battery of psychometric examinations administered before and 12 weeks after therapy. The cancer-pain group reported significant reduction in pain on serial visual pain analogue scales at 12 weeks compared with no change in the nonmalignant-pain group reports despite a much lower baseline report in the cancer group. Both groups of patients reduced their oral narcotic requirement significantly during continuous intraspinal morphine infusion. While the cancer patients took more oral narcotic at baseline, at 12 weeks no difference existed in oral intake between the two groups. Both groups required significant serial increases in infused morphine, indicating that spinal opiate receptor tolerance occurs. The results of this study confirm the sustained analgesic efficacy reported earlier in cancer-related pain syndromes, thus supporting further cautious expansion of this therapy within the cancer-related pain population. In contrast, a poor response was seen in the nonmalignant-pain group, consistent with the unsatisfactory responses to many potentially analgetic approaches to chronic nonmalignant pain. We are thus discouraged from further use of this therapy in the patient with chronic nonmalignant pain.

UR - http://www.scopus.com/inward/record.url?scp=84944283970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944283970&partnerID=8YFLogxK

U2 - 10.1001/jama.1983.03340170062030

DO - 10.1001/jama.1983.03340170062030

M3 - Article

C2 - 6688832

AN - SCOPUS:84944283970

VL - 250

SP - 2336

EP - 2339

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 17

ER -